Estrogen plus progestin did not improve health-related quality of life in postmenopausal women 50 to 79 years of age

November 2003
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p60
Academic Journal
This article discusses whether estrogen plus progestin (EPP) is more effective than placebo for improving health-related quality of life in post-menopausal women. Women were allocated to EPP therapy. Improvement from baseline in physical functioning, bodily pain, and sleep disturbance was greater in the EPP group than in the placebo group. However, the improvements were small and not clinically meaningful.


Related Articles

  • Estrogen plus progestin did not improve health-related quality of life in postmenopausal women 50 to 79 years of age: COMMENTARY. Cheung, Angela M. // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p60 

    The large-scale trial by researchers J. Hays and colleagues has confirmed that physicians should not prescribe estrogen plus progestin (EPP) therapy to postmenopausal women in the general population for prevention of chronic diseases or for improvement of health-related quality of life (HRQL)....

  • Estrogen plus progestin increased coronary heart disease and breast cancer events in postmenopausal women. Lowe, Julia // ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p41 

    Presents information on a study that investigated the risks and benefits of estrogen plus progestin in healthy postmenopausal women. Design of the study; Analysis of the incidence of diseases between the placebo-controlled trial versus estrogen plus progestin; Rate of unfavorable and favorable...

  • Postmenopausal Hormone Therapy: Impact on Menopause-Related Symptoms, Chronic Disease and Quality of Life. van der Mooren, Marius Jan; Kenemans, Peter // Drugs;2004, Vol. 64 Issue 8, p821 

    Quality of life in climacteric and postmenopausal women is often compromised. This overview addresses the many factors that may interfere with health and well-being in such women. Hormonal changes during the menopausal transition, finally resulting in estrogen deficiency, play a pivotal role in...

  • Combined HRT improves HRQOL in older women.  // PharmacoEconomics & Outcomes News;9/6/2008, Issue 561, p8 

    The article focuses on the capability of combined hormone replacement therapy (HRT) to improve health-related (HR) quality of life (QOL) in women who begin treatment years after menopause, based on research. The postmenopausal women who participated in the study were from general practices in...

  • Hormone replacement therapy preparations. Sturdee, David W. // Journal of the British Menopause Society;2000, Vol. 6 Issue 1, p34 

    The article reports on licensed hormone replacement therapy regimens in Great Britain. The most suitable initial treatment for 80 percent of women is oral estrogen. About 15 percent of women have transdermal estrogen. For over 50 years, pellets of crystallized estradiol have been available for...

  • Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Richard L. Tannen; Mark G. Weiner; Dawei Xie; Kurt Barnhart // Human Reproduction;Jun2007, Vol. 22 Issue 6, p1769 

    BACKGROUND In the Womens Health Initiative Randomized Controlled Trial (WHI RCT), estrogen-only treatment compared with combined estrogen–progestin treatment resulted in less coronary artery disease, no increase in breast cancer and no reduction in colorectal cancer. Since we...

  • Monophasic Estrogen-Progestogen Therapy and Sexuality in Postmenopausal Women. Fonseca, A. M.; Bagnoli, V. R.; Penteado, S. R. L.; Paixão, J. S.; Cavalcanti, A. L.; Pinotti, J. A. // Clinical Drug Investigation;2007, Vol. 27 Issue 2, p131 

    OBJECTIVE: This study aimed to evaluate the effects of monophasic estrogen-progestogen therapy on the sexuality and climacteric symptoms of postmenopausal women. PATIENTS AND METHODS: A prospective, randomised, double-blind, crossover, placebo-controlled, single-centre study was carried out...

  • Alzheimer’s disease: the impact of age-related changes in reproductive hormones. Simpkins, J. W.; Yang, S.-H.; Wen, Y.; Singh, M. // Cellular & Molecular Life Sciences;Feb2005, Vol. 62 Issue 3, p271 

    Two classes of ovarian steroids, estrogens and progestins, are potent in protecting neurons against acute toxic events as well as chronic neurodegeneration. Herein we review the evidence for neuroprotection by both classes of steroids, provide plausible mechanisms for these potent...

  • Trisequens.  // Royal Society of Medicine: Medicines;2002, p550 

    The article presents information on trisequens, a proprietary, prescription-only compound preparation of the estrogen estradiol and the progestogen norethisterone. Trisequens can be used to treat menopausal problems and also for osteoporosis prevention. It is available in tablet form.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics